Precision Medicine in Early-stage NSCLC

CE / CME

Precision in Early-Stage NSCLC Care: ​Community Workshop on the Optimal​ Integration of Biomarker-Driven Therapy

Nurses: 0.75 Nursing contact hour

Pharmacists: 0.75 contact hour (0.075 CEUs)

Physicians: maximum of 0.75 AMA PRA Category 1 Credit

Released: October 18, 2024

Expiration: April 17, 2025

Karen Reckamp
Karen Reckamp, MD, MS

Pretest

Progress
1 2 3
Course Completed
Please answer the questions below.
1.

Case: Stage IIB NSCLC



  • 64-yr-old female presented with chest discomfort and cardiac work up was negative

  • CT chest

    • 1.3-cm left upper lobe nodule

    • No abnormal lymphadenopathy



  • CT A/P without evidence of disease

  • Bronchoscopy with FNA of the left upper lobe nodule

    • Non-small-cell carcinoma, consistent with adenocarcinoma



  • PET/CT with uptake in the left upper lobe §MRI brain was normal

  • She underwent robotic VATS LUL lobectomy with mediastinal LND

Which of the following most accurately describes the minimum recommended biomarker testing for patients diagnosed with early-stage NSCLC?

2.

Based on available evidence, patients with resectable early-stage NSCLC and which of the following levels of PD-L1 expression may benefit from perioperative (neoadjuvant and adjuvant) nivolumab, durvalumab, or pembrolizumab?